FDA warned Salvacion USA that Covixyl Nasal Spray is an unapproved new drug sold with antiviral claims.
What happened
FDA reviewed the Covixyl website and its X and Facebook pages on October 10, 2023. FDA found claims that Covixyl Nasal Spray blocks airborne viruses such as SARS-CoV-2, rotavirus, H1N1, and RSV and protects against infection for up to 6 hours, and it said no FDA-approved application is in effect for the product.
What FDA found
FDA says Covixyl Nasal Spray is a drug because it is intended to prevent or treat disease and affect the structure or function of the body.
section 201(g)(1)(B) and/or 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), (C)FDA says the product is a "new drug" because it is not generally recognized as safe and effective for its claimed uses.
section 201(p) of the FD&C Act, 21 U.S.C. 321(p)FDA says the product was introduced or delivered for introduction into interstate commerce without an approved drug application.
sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)FDA cited website and social media claims that Covixyl blocks airborne viruses, including SARS-CoV-2, rotavirus, H1N1, and RSV, for up to 6 hours.
21 CFR 201.128 (intended use)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with supporting documents. If corrective action cannot be completed in that time, the company must state why and when it will be completed.
Who should pay attention
- retailers and online sellers of Covixyl Nasal Spray
- companies making nasal sprays with antiviral or disease-prevention claims
- consumers who bought products marketed to block viruses
This is a summary. Read the original letter on fda.gov.